CCM
HBIO icon

Corsair Capital Management’s Harvard Bioscience HBIO Stock Holding History

Corsair Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$608K Buy
124,810
+13,941
+13% +$77.9K 0.09% 79
2025
Q4 		$741K Buy
110,869
+100,869
+1,009% +$598K 0.12% 65
2025
Q3 		$43.9K Buy
+10,000
New +$47.4K 0.01% 159
2024
Q4 		– Sell
-2,336
Closed -$62.8K – 130
2024
Q3 		$62.8K Buy
+2,336
New +$68.8K 0.01% 111
2024
Q1 		– Sell
-6,654
Closed -$356K – 101
2023
Q4 		$356K Buy
+6,654
New +$300K 0.11% 62

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Corsair Capital Management's HBIO Position: Q1 2026 in Review

Corsair Capital Management increased its Harvard Bioscience (HBIO) stake by 13% in Q1 2026, buying an estimated $77.9K and bringing the position to 124,810 shares worth $608K. The position accounts for 0.09% of the portfolio, ranked #79.

Corsair Capital Management first reported a position in HBIO in Q4 2023 and has held it in 5 quarters since. The position peaked at $741K in Q4 2025. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Corsair Capital Management held 124,810 shares of Harvard Bioscience worth $608K as of Q1 2026.
  • Corsair Capital Management bought 13,941 Harvard Bioscience shares in Q1 2026, an estimated $77.9K.
  • Harvard Bioscience made up 0.09% of Corsair Capital Management's portfolio in Q1 2026, its #79 holding.
  • Corsair Capital Management first reported a position in Harvard Bioscience in Q4 2023 and has held it in 5 quarters since.
  • Corsair Capital Management's Harvard Bioscience position peaked at $741K in Q4 2025.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Corsair Capital Management's 13F filing for Q1 2026, filed 15 May 2026.